Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design

International Journal of Pharmaceutics

Volumn 342, Issue 1-2, 2007, Pages 168-175

  Vandecruys, Roger ^a   Peeters, Jef ^a   Verreck, Geert ^a   Brewster, Marcus E ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Cellulosic polymers; Co solvents; Cyclodextrins; Excipient; PVP; Supersaturation; Surfactants

Indexed keywords

CREMOPHOR; CYCLODEXTRIN; POLYSORBATE 20; POVIDONE; TOCOFERSOLAN;

ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG SOLUTION; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCREENING;

ABSORPTION; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLIZATION; DIFFUSION; DOGS; DRUG STABILITY; EXCIPIENTS; INDICATORS AND REAGENTS; MASS SPECTROMETRY; PHARMACEUTICAL SOLUTIONS; RHEOLOGY; SOLVENTS; SURFACE TENSION; TABLETS;

EID: 34547882770     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.05.006     Document Type: Article

References (52)

1. Amidon G.L., Lennemans H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavaliability. Pharm. Res. 12 (1995) 413-420
2. Appel, L.E., Babcock, W.C., Friesen, D.T., Ray, R.J., Shamblin, R.M., Smithey, D.T., 2006. Pharmaceutical dosage forms comprising a low solubility drug and polymer. International Patent Appl: WO2006024944 A2.
3. Brewster, M.E., Vandecruys, R., Peeters, J., Verreck, G., Loftsson, T., 2006. Interactions of 2-hydroxypropyl-β-cyclodextrin and sulfobutylether-β-cyclodextrin with itraconazole: stabilization of supersaturated drug solutions. J. Pharm. Sci. (submitted for publication).
4. Brewster M.E., Verreck G., Chun I., Rosenblatt J., Mensch J., Van Dijck A., Noppe M., Arien T., Bruining M., and Peeters J. The use of polymer-based electrospun nanofibers containing amorphous drug dispersions in the delivery of poorly water-soluble pharmaceuticals. Pharmazie 59 (2004) 387-391
5. Brewster M., Vandecruys R., Verreck G., Noppe M., and Peeters J. A novel cyclodextrin-containing glass thermoplastic systems (GTS) for formulating poorly water soluble drug candidates: preclinical and clinical results. J. Incl. Phenom. Macro. Chem. 44 (2003) 35-38
6. Constantinides P.P., Han J., and Davis S.S. Advances in the use of tocols as drug delivery vehicles. Pharm. Res. 23 (2006) 243-255
7. Crew, M.D., Shanker, R.M., Smithey, D.T., Miller, W.K., Friesen, D.T., 2005. Stabilized pharmaceutical solid compositions of low solubility drugs, poloxamers and stabilizing polymers. International Patent Appl: WO 2005065656 A2.
8. Davis M.E., and Brewster M.E. Cyclodextrin-based pharmaceutics: past, present, future. Nat. Rev. Drug Discov. 3 (2004) 1023-1035
9. Davis A.F., and Hadgraft J. Effect of supersaturation on membrane transport. 1. Hydrocortisone acetate. Int. J. Pharm. 76 (1991) 1-8
10. Dias M., Raghavan S., Pellett M., and Hadgraft J. The effect of β-cyclodextrins on the permeability of diclofenac from supersaturated solutions. Int. J. Pharm. 263 (2003) 173-181
11. Dressman J.B., Amidon G.L., Reppas C., and Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15 (1998) 11-22
12. Forster A., Rades T., and Hempenstall J. Selection of suitable drug and excipient candidates to prepare glass solutions by melt extrusion for immediate release oral formulations. Pharm. Tech. Eur. 14 (2002) 27-37
13. Gao P., and Morozowich W. Development of supersaturable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly water soluble drugs. Expert Opin. Drug Deliv. 3 (2006) 97-110
14. Gao P., Guyton M.E., Huang T., Bauer J., Stefanski K., and Lu L. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturable formulations. Drug Dev. Ind. Pharm. 30 (2004) 221-229
15. Guzmán H., Tawa M., Zhang Z., Ratanabanangkoon P., Shaw P., Mustonen P., Gardner C., Chen H., Moreau J., Almarsson O., and Remenar J. Spring and parachute approach to designing solid celecoxib formulations having enhanced oral absorption. AAPS J. 6 (2004) T2189
16. Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int. J. Pharm. 184 (1999) 1-6
17. Humberstone A., and Charman W. Lipid-vased vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 25 (1997) 103-128
18. Iervolino M., Raghavan S., and Hadgraft J. Membrane penetration enhancement of ibuprofen using supersaturation. Int. J. Pharm. 198 (2000) 229-238
19. Kim C., and Park J. Solubility enhancement for oral delivery: can chemical structure modification be avoided?. Am. J. Drug Deliv. 2 (2004) 113-130
20. Kohori N., Yamayoshi Y., Xin H., Iseki K., Sato N., Todo S., and Miyazaki K. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J. Pharm. Pharmacol. 51 (1999) 159-164
21. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2 (2004) 711-715
22. Li L., Abubaker O., and Shao Z. Characterization of poly(ethylene oxide) as a drug carrier in hot-melt extrusion. Drug Dev. Ind. Pharm. 32 (2006) 991-1002
23. Lindfors L., Skantze P., Skantze U., Rasmusson M., Zackrisson A., and Olsson U. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir 22 (2006) 906-910
24. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computatorial approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
25. Lipinski C.A. Avoiding investment in doomed drugs. Curr. Drug Discov. 1 (2001) 17-19
26. Liu R. Water-insoluble drug formulation (2000), Interpharm Press, Englewood, CO
27. Loftsson T., Brewster M.E., and Masson M. Role of cyclodextrins in improving oral delivery. Am. J. Drug Deliv. 2 (2004) 261-275
28. Loftsson T., and Brewster M.E. Pharmaceutical applications of cyclodextrins. I. Drug solubilization and stabilization. J. Pharm. Sci. 85 (1996) 1017-1025
29. Ma X., Taw J., and Chiang C. Control of drug crystallization in transdermal matrix systems. Int. J. Pharm. 142 (1996) 115-119
30. Macie C.M.G., and Grant D.J.W. Crystal growth in pharmaceutical formulation. Pharm. Int. 1986 (1986) 233-237
31. Merisko-Liversidge E., Liversidge G., and Cooper E. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18 (2003) 113-120
32. Michaud M., and Icart S. Determination of the substitution of hydroxypropylbetadex using Fourier transform infrared spectrophotometry. Pharmeuropa 13 (2001) 714-716
33. Moser K., Kriwet K., Froehlich C., Kali Y., and Guy R.H. Supersaturation: enhancement of skin penetration and permeability of a lipophilic drug. Pharm. Res. 18 (2001) 1006-1011
34. Moser K., Kriwet K., Kali Y., and Guy R.H. Stabilization of supersaturated solutions of a lipophilic drug for dermal delivery. Int. J. Pharm. 224 (2001) 169-176
35. Müller R.H., Böhm B.H., and Grau M.J. Nanosuspensionen - formulierungen für schwerlösliche Arzneistoffe mit geringer Bioverfügbarkeit. 1. Mitteilung: Herstellung und Eigenshaften. Pharm. Ind. 61 (1999) 74-78
36. Peeters J., Neeskens P., Tollenaere J., and Van Remoortere P. Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with itraconazole at pH 2, 4 and 7. J. Pharm. Sci. 91 (2002) 1414-1422
37. Prentis R.A., Lis Y., and Walker S.R. Pharmaceutical innovation by seven UK-owned pharmaceutical companies. Br. J. Clin. Pharmacol. 25 (1988) 387-396
38. Raghavan S.L., Trividic A., Davis A.F., and Hadgraft J. Crystallization of hydrocortisone acetate: influence of polymers. Int. J. Pharm. 212 (2001) 213-221
39. Raghavan S.L., Schuessel K., Davis A., and Hadgraft J. Formation and stabilization of triclosan colloidal suspension using supersaturated systems. Int. J. Pharm. 261 (2003) 153-158
40. Rajewski R.A., and Stella V.J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 85 (1996) 1142-1169
41. Rambali B., Verreck G., Baert L., and Massart D. Itraconazole formulation studies of the melt-extrusion process with mixture design. Drug Dev. Ind. Pharm. 29 (2003) 641-652
42. Rangel-Yagui C.O., Pessoa A., and Tavares L.C. Micellar solubilization of drugs. J. Pharm. Pharmaceut. Sci. 8 (2005) 147-163
43. Rodriguez-Hornedo N., and Murphy D. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J. Pharm. Sci. 88 (1999) 651-660
44. Six K., Berghmans H., Leuner C., Dressman J., Van Werde K., Mullens J., Benoist L., Thimon M., Meublat L., Verreck G., Peeters J., Brewster M., and Van den Mooter G. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion. Part 2. Pharm. Res. 20 (2003) 1047-1054
45. Strickley R.G. Solubilizing excipients in oral and liquid formulations. Pharm. Res. 21 (2004) 201-230
46. Thompson D.O. Cyclodextrin-enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Therap. Drug Carrier Syst. 14 (1997) 1-104
47. Torres-Labandeira J., Davignon P., and Pitha J. Oversaturated solutions of drugs in hydroxypropylcyclodextrins: parenteral preparation of pancratistatin. J. Pharm. Sci. 80 (1990) 384-386
48. Uekama K., Ikegami K., Wang Z., Horiuchi Y., and Hirayama F. Inhibitory effect of 2-hydroxypropyl-β-cyclodextrin on crystal growth of nifedipine during storage: superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30. J. Pharm. Pharmacol. 44 (1992) 73-78
49. Urbanetz N., and Lippold B. Solid dispersions of nimodipine and polyethylene glycol 2000: dissolution properties and physico-chemical characterization. Eur. J. Pharm. Biopharm. 59 (2005) 107-118
50. Verreck G., Vandecruys R., De Conde V., Baert L., Peeters J., and Brewster M.E. The use of three different solid dispersion formulations: melt extrusion, film-coated beads and a glass thermoplastic system to improve the bioavailability of a novel microsomal triglyceride transfer protein (MTP) inhibitor. J. Pharm. Sci. 93 (2004) 1217-1228
51. Verreck G., Six K., Van den Mooter G., Baert L., Peeters J., and Brewster M.E. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion. Part 1. Int. J. Pharm. 251 (2003) 165-174
52. Wu W., and Nancollas G.H. A new understanding of the relationship between solubility and particle size. J. Solution Chem. 27 (1998) 521-531